RESEARCH TRIANGLE PARK, N.C., & BOSTON--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into ...

BioCryst Pharmaceuticals has seen its Fair Value Estimate rise from $16.73 to $18.50, signaling a more optimistic view of the company’s intrinsic worth. At the same time, the Discount Rate has inched ...

(Reuters) -BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, as it looks to expand its portfolio of treatments for rare ...

BioCryst is acquiring Astria Therapeutics for ~$700M, aiming to bolster its hereditary angioedema portfolio with navenibart. The deal targets market leader Takhzyro by offering navenibart's less ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that the companies have entered into a definitive agreement under which BioCryst has agreed ...

Investing.com - Oppenheimer downgraded Astria Therapeutics (NASDAQ:ATXS) from Outperform to Perform following the company’s acquisition agreement with BioCryst Pharmaceuticals. The stock, which has ...

RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) and Astria Therapeutics, Inc. (ATXS) today announced that the companies have entered ...

Having already established a commercial infrastructure for its oral hereditary angioedema (HAE) drug Orladeyo and eager to pinpoint the source of its future growth, BioCryst Pharmaceuticals has struck ...

Investing.com - Citizens downgraded Astria Therapeutics (NASDAQ:ATXS) stock rating from Market Outperform to Market Perform on Wednesday. The stock has shown remarkable momentum, surging 38% in the ...

Oct 14 (Reuters) - BioCryst Pharmaceuticals (BCRX.O), opens new tab said on Tuesday it would buy Astria Therapeutics (ATXS.O), opens new tab in a cash-and-stock deal valued at about $700 million, ...